<\/span><\/h2>\n\n\n\n1.The Legal Issues \u2013<\/h3>\n\n\n\n
According\nto the Patent Act of 1970, a product or process can only be eligible for a\npatent if it involves innovation and complete disclosure. However, when considering\ninnovations in the biotechnology field, it becomes evident that they may be\nperceived as naturally occurring subject matter, falling within the exclusion\nclauses of Section 3 of the Act.<\/strong><\/p>\n\n\n\nFurthermore,\nusing a substance that is naturally available but excluding it from the general\npublic may be considered against the public interest, thereby excluding it from\npatentability. Some cases describe this as the transformation of\n“naturally occurring material created by a higher power” into private\nobjects using technology.<\/p>\n\n\n\n
An\nillustrative case highlighting this is Funk\nBros. v. Inoculant Co<\/strong>., which involved culturing Rhizobia to immunize\nleguminous plants. The court ruled that the inherent characteristics of\nbacteria were merely a “work of nature” and, therefore, not\npatentable.<\/p>\n\n\n\nHowever,\nthe case of Diamond v. Chakrabarty presents a contrasting perspective. In this\ncase, the U.S. Supreme Court adopted a liberal approach and granted a patent\nfor a genetically improved bacterial species. The court focused on the\ninventive step taken to harness the bacteria’s unique capability. It emphasized\nthat the term “manufacture” encompassed all man-made creations.<\/p>\n\n\n\n
Following\nthis landmark decision, several patents were granted with little regard for\nmoral considerations. The need for more clarity regarding when an invention\nshould be examined from the standpoint of public morality raises the question\nof when human intervention alone is sufficient to deem an invention patentable,\nparticularly in the context of Genetically Modified Organisms (GMOs).\nFurthermore, inconsistent court rulings need to establish clear guidelines\nconcerning patentable life forms.<\/p>\n\n\n\n
2.The Moral and Ethical Issues-<\/h3>\n\n\n\n
The\ninclusion of genetically modified\norganisms <\/strong>(GMOs) in the realm of patentable inventions has sparked ethical\nand moral debates, questioning whether these actions amount to assuming the\nrole of a higher power and degrading the sanctity of life in pursuit of private\ninterests.<\/p>\n\n\n\nA\ncritical case to consider is Relaxin, where the court differentiated between\npatenting a single gene and patenting human life itself. The court reasoned\nthat since cloning technology had not advanced to the stage where an entire\nhuman could be cloned from a single gene, the two could not be equated.\nAdditionally, particular inventions hold significant societal importance,\nmaking their patentability apparent. In the case of isolating Relaxin for\ngenetic coding, it was considered more than a mere discovery.<\/p>\n\n\n\n
In\nanother case before the European Courts, the patentability of a genetically\nmodified plant faced opposition based on moral grounds. During this case, the\nBoard explained the terms “morality” and “public order.”\nHowever, these concepts vary among nations, as the criteria for determining\nwhat is moral or disruptive to public order largely depend on the collective\nconscience of different segments of society.<\/p>\n\n\n\n
For\nmany, patenting life forms is often deemed immoral, as manipulating genes can\npresent a perspective where life is reduced to a mere commodity, exploited for\nprofit by private entities or individuals.<\/p>\n\n\n\n
3. Ownership Issues-<\/h3>\n\n\n\n
The\nissue of ownership rights over modified life forms has been a subject of\ndiscussion in various instances. For instance, consider the case of the\nT-Lymphocyte, where a patent was granted based on an invention derived from a\ncancer patient’s spleen without their consent or knowledge. This action led to\nlegal disputes and raised questions about whether researchers should obtain explicit\nconsent to claim ownership rights over genetically modified materials.\nAdditionally, what benefits should be provided to contributors involved in the\nresearch?<\/p>\n\n\n\n
Despite\nthese concerns, it is crucial to recognize that the primary objective of\npatenting life forms is to benefit humanity as a whole. The commercial aspect\nshould be seen in collaboration rather than in the context of promoting the\npublic interest. It is essential to acknowledge that research can only be\nincentivized if a fair reward exists. Granting patents encourages efforts\ntowards advancing society, particularly in areas that aim to improve quality of\nlife or revolutionize healthcare. Temporary monopolization is seen as a minor\ntrade-off for the greater goal.<\/p>\n\n\n\n
However,\nother aspects can lead to discontents, such as the potential advantages\ndeveloped countries have over developing ones and their involvement in the\nappropriation of biological materials from various communities. It is evident\nin the pharmaceutical industry, where affluent nations derive financial\nbenefits from others by requiring periodic payments for the use of patented\ninventions deemed essential for survival.<\/p>\n\n\n\n